• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Celldex Therapeutics Inc.

    6/26/26 4:01:33 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CLDX alert in real time by email
    S-8 1 tm2617852d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on June 26, 2026

    Registration No. 333- [     ]

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    CELLDEX THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   13-3191702
    (State or other jurisdiction   (I.R.S. employer
    of incorporation or organization)   identification number)

     

    Perryville III Building

    53 Frontage Road, Suite 220

    Hampton, New Jersey 08827

    (908) 200-7500

    (Address of principal executive offices; zip code)

     

    Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan

    (Full title of the plan)

     

    Sam Martin

    Chief Financial Officer

    CELLDEX THERAPEUTICS, INC.

    Perryville III Building

    53 Frontage Road, Suite 220

    Hampton, New Jersey 08827

    (908) 200-7500 

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Anthony O. Pergola, Esq. 

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    (212) 262-6700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
    Non-accelerated filer ¨ Smaller reporting company ¨
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement is being filed by the registrant, Celldex Therapeutics, Inc. (the “Company”), for the purpose of registering an additional 3,400,000 shares of common stock, par value $0.001 per share (“Common Stock”), to be issued under the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended, effective as of June 25, 2026) (the “2021 Plan”), pursuant to General Instruction E on Form S-8 (Registration of Additional Securities).

     

    The contents of the original registration statement on Form S-8 for the 2021 Plan filed on June 16, 2021 (File No. 333-257137), the registration statement on Form S-8 for the 2021 Plan filed on June 21, 2023 (File No. 333-272804), the registration statement on Form S-8 for the 2021 Plan filed on June 14, 2024 (File No. 333-280207) and the registration statement on Form S-8 for the 2021 Plan filed on June 6, 2025 (File No. 333-287839) are hereby incorporated by reference and made a part hereof. Any items in the Company’s Registration Statements on Form S-8 (File No. 333-257137, File No. 333-272804, File No. 333-280207 and File No. 333-287839) not expressly changed hereby shall be as set forth in the Company’s Registration Statements on Form S-8 (File No. 333-257137, File No. 333-272804, File No. 333-280207 and File No. 333-287839)). The stockholders of the registrant approved amending the 2021 Plan for this purpose at the annual meeting of stockholders held on June 25, 2026.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Certain Documents by Reference

     

    The Securities and Exchange Commission allows us to “incorporate” into this registration statement information we file with other documents. This means that we may disclose important information to you by referring to other documents that contain that information. The information incorporated by reference is considered to be part of this registration statement, and information we file later with the Securities and Exchange Commission will automatically update and supersede this information. We incorporate by reference the documents listed below, except to the extent information in those documents is different from the information contained in this registration statement:

     

      · Our Annual Report on Form 10-K for the year ended December 31, 2025, filed on February 25, 2026.

     

      · Our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed on May 7, 2026.

     

      · Our Current Reports on Form 8-K filed with the Securities and Exchange Commission on April 2, 2026 and June 26, 2026 (in each case, except to the extent furnished but not filed).
         
      · Our Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 29, 2026 (solely with respect to those portions incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2025).

     

      · The description of the securities contained in the Company’s Registration Statement on Form 8-A filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as the description therein has been updated and superseded by the description of the Company’s capital stock contained in Exhibit 4.3 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on February 28, 2023, including any amendments or reports filed for the purpose of updating such description.

     

    All documents subsequently filed by us with the Securities and Exchange Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this registration statement, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

     

    Item 8. Exhibits

     

    The exhibits accompanying this registration statement are listed on the accompanying exhibit index.

     

    -2-

     

     

    EXHIBIT INDEX

     

    Exhibit
    Number
      Description
         
    5.1   Opinion of Lowenstein Sandler LLP*
    23.1   Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm of Celldex Therapeutics, Inc.*
    23.2   Consent of Lowenstein Sandler LLP (filed as part of Exhibit 5.1).*
    24.1   Power of Attorney (contained on signature page to this registration statement on Form S-8)*
    99.1   Amendment No. 4 to Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 26, 2026)
    107   Filing Fee Table*

     

    * Filed herewith.

     

    -3-

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Hampton, State of New Jersey, on June 26, 2026.

     

    CELLDEX THERAPEUTICS, INC.  
       
    By: /s/ Anthony S. Marucci  
      Anthony S. Marucci  
      President and Chief Executive Officer  
      (Principal Executive Officer)  
         
    By: /s/ Sam Martin  
      Sam Martin  
      Senior Vice President and Chief Financial Officer  
      (Principal Financial Officer and Principal Accounting Officer)  

     

    KNOW ALL BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Anthony S. Marucci and Sam Martin, and each of them singly, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

     

    -4-

     

     

    Signature   Title   Date
    /s/ ANTHONY S. MARUCCI   President, Chief Executive Officer, and Director   June 26, 2026
    Anthony S. Marucci   (Principal Executive Officer)    
             
    /s/ SAM MARTIN   Senior Vice President,   June 26, 2026
    Sam Martin   Chief Financial Officer and Treasurer
    (Principal Financial and Accounting Officer)
       
             
    /s/ HARRY H. PENNER, JR.   Director, Chair of the Board of Directors   June 26, 2026
    Harry H. Penner, Jr.        
             
    /s/ KEITH L. BROWNLIE   Director   June 26, 2026
    Keith L. Brownlie        
             
    /s/ CHERYL L. COHEN   Director   June 26, 2026
    Cheryl L. Cohen        
             
    /s/ HERBERT J. CONRAD   Director   June 26, 2026
    Herbert J. Conrad        
             
    /s/ RITA I. JAIN, M.D.   Director   June 26, 2026
    Rita I. Jain, M.D.        
             
    /s/ JAMES J. MARINO   Director   June 26, 2026
    James J. Marino        
             
    /s/ GARRY A. NEIL, M.D.   Director   June 26, 2026
    Garry A. Neil, M.D.        
             
    /s/ DENICE TORRES   Director   June 26, 2026
    Denice Torres        

     

    -5-

     

    Get the next $CLDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLDX

    DatePrice TargetRatingAnalyst
    4/20/2026$45.00Underweight → Overweight
    Barclays
    3/23/2026$44.00Peer Perform → Outperform
    Wolfe Research
    10/21/2025$48.00Outperform
    Mizuho
    10/13/2025$25.00Underweight
    Barclays
    4/28/2025$64.00Buy
    Canaccord Genuity
    3/20/2025$46.00Overweight
    Morgan Stanley
    2/13/2025$44.00Buy
    UBS
    10/7/2024$70.00Buy
    Citigroup
    More analyst ratings

    $CLDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

    Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSUSeven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free Barzolvolimab has potential to shift treatment goals from symptom control to disease modificationResults continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026 HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at

    6/14/26 10:21:00 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

    CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseasesCDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells without measurably impacting other KIT functionsRapid, profound, dose-dependent, and durable reductions in serum tryptase observedWell-tolerated at all dose levels First company to demonstrate that neutralizing soluble SCF can selectively inhibit KIT signaling in mast cells HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody

    6/14/26 5:15:00 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

    -- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that three presentations from the barzolvolimab and CDX-622 programs will be shared at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress being held in Istanbul, Türkiye, on June 12-15, 2026. Results supporting Celldex's leadership and barzolvolimab's first-in-class, best-in-disease profile in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) will be presented in two flash talks. New, first-in-human results from the Phase 1 t

    6/10/26 4:01:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Marucci Anthony S bought $308,430 worth of shares (11,500 units at $26.82), increasing direct ownership by 40% to 40,284 units (SEC Form 4)

    4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

    11/12/24 8:01:10 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    SEC Filings

    View All

    SEC Form S-8 filed by Celldex Therapeutics Inc.

    S-8 - Celldex Therapeutics, Inc. (0000744218) (Filer)

    6/26/26 4:01:33 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Celldex Therapeutics, Inc. (0000744218) (Filer)

    6/26/26 8:43:39 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SCHEDULE 13G filed by Celldex Therapeutics Inc.

    SCHEDULE 13G - Celldex Therapeutics, Inc. (0000744218) (Subject)

    5/12/26 10:18:40 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP AND CFO Martin Samuel Bates exercised 4,817 shares at a strike of $10.38, increasing direct ownership by 17% to 32,942 units (SEC Form 4)

    4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

    1/6/26 4:23:48 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SR. VP & CBO Pepin Ronald exercised 19,333 shares at a strike of $5.47, increasing direct ownership by 2,530% to 20,097 units (SEC Form 4)

    4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

    12/17/25 4:06:34 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SVP & GENERAL COUNSEL Jimenez Freddy A. sold $121,210 worth of shares (4,166 units at $29.09), decreasing direct ownership by 12% to 30,796 units (SEC Form 4)

    4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

    12/8/25 4:20:35 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Celldex Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Celldex Therapeutics from Underweight to Overweight and set a new price target of $45.00

    4/20/26 8:20:25 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Therapeutics upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Celldex Therapeutics from Peer Perform to Outperform and set a new price target of $44.00

    3/23/26 8:22:59 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Mizuho initiated coverage on Celldex Therapeutics with a new price target

    Mizuho initiated coverage of Celldex Therapeutics with a rating of Outperform and set a new price target of $48.00

    10/21/25 7:19:21 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Leadership Updates

    Live Leadership Updates

    View All

    Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

    HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30 years of strategic, commercial launch and operating P&L leadership across the biopharmaceutical, medical device and consumer health technology sectors. Ms. Lawver succeeds Richard Wright, who will retire from Celldex following more than a decade of dedicated leadership and service. "We are thrilled to welcome Teri to the Celldex leadership team," said Anthony Marucci, Co-founder, President, and Chief Executive Officer of Celldex. "Teri brings an extraordina

    11/10/25 8:01:00 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

    HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors. "We are excited to welcome Denice to the Celldex Board of Directors," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "Denice's extensive leadership experience across both the pharmaceutical and consumer healthcare sectors brings a deep operational and commercial perspective to our team. Her track record of driving strategic growth and operational excellence will be instrumental as we advance our clinical programs and continue building our organization." Ms. Torres added, "

    6/6/25 8:01:00 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

    HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company's Board of Directors. "We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in the Company's trajectory," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. "Dr. Jain's deep background in drug development strongly complements our Board's skills and experiences, and we look forward to her contributions as we continue to advance our programs into later stage development." Dr. Jain added, "I am excited to join Celldex, whose emerging data suggests tha

    2/16/23 4:01:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Financials

    Live finance-specific insights

    View All

    Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

    Study met primary endpoint demonstrating barzolvolimab's ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a primary driver in EoE Favorable safety profile demonstrated for barzolvolimab 300 mg Q4 weekly dosing regimenCompany to host webcast today at 4:30 pm ET HAMPTON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported topline results from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus. Identifying the key drivers of

    8/19/25 4:01:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

    Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1)KIT related tolerability events demonstrated to be reversible Enrollment to Phase 3 CSU trials ongoingCompany to host webcast today at 6:00 pm ET HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast c

    6/12/25 6:01:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

    First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 developmentCompany to host webcast call Monday at 8:00 am ET HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humaniz

    10/26/24 5:43:20 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

    SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

    11/14/24 7:47:25 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

    SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

    11/14/24 12:18:08 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

    SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

    11/14/24 6:12:56 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care